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This thesis draws together a series of publications based on work 
carried out between 2008 and 2018, which examines various aspects of 
pharmacy regulation as it is reformed in response to changing 
perspectives on healthcare. 
The regulated activities of pharmacy include supply of medicines, 
handling of controlled substances, and maintenance of registration with 
the General Pharmaceutical Council. The legal underpinnings of each of 
these activities has undergone significant change in the last ten years. 
Failing to stay abreast of changes to pharmacy law, or to understanding 
how these changes affect their practice, can leave pharmacists open to 
criminal prosecution, civil actions, and fitness to practise proceedings. 
This regulatory environment can create the potential for moral distress 
to occur as practitioners are prevented from acting in congruence with 
their own moral agency. 
The submission includes thirteen pieces of work discussed under four 
headings: the three legally regulated activities mentioned above; and a 
fourth category dealing with moral considerations raised with respect to 
conscientious objection and moral distress. Initial analysis of the 
changing legal landscape identifies possible triggers for moral distress, 
which are subsequently factored into the development of a tool to 
measure this phenomenon in community pharmacists. 
The earlier publications included in this thesis have had a significant 
impact on several aspects of pharmacy regulation, while informing the 
direction of the later work, which seeks to provide an insight into the 
incidence of moral distress experienced by community pharmacists and 
provide researchers with a set of tools with which to extend the scope 
of the literature in this area. 
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This submission describes a selection of publications, each of which 
contemporaneously addresses a significant change in an aspect of 
pharmacy law, and critically examines the effect that these changes 
have on the working practices of pharmacy professionals. The 
consequences of specific aspects of pharmacy law on the moral 
agency of pharmacists are then examined in the context of moral 
distress. 
Moral distress was first described as the feeling that arose “when one 
knows the right thing to do, but institutional constraints make it 
nearly impossible to pursue the right course of action”.[1](p.6) This 
definition has undergone numerous refinements by subsequent 
authors and has broadened in scope to incorporate experiences of 
moral anguish that arise in response to the inability to enact moral 
judgements due to a broad range of constraints, including legal 
requirements, professional regulations, insufficient resources, and 
personal limitations. It may be thought of as resulting from a barrier 
an individual's ability to make moral judgments based on some 
notion of right and wrong, or their “moral agency”. 
Initially, research focused predominately on the experience of nurses 
due, in part, to the historical perception of nursing as subordinate to 
other disciplines within the medical hierarchy, and therefore the most 
likely to experience distress as a result of the restrictions imposed by 
others.[2] As the conceptual boundaries of moral distress have 
developed, so too has the research interest in the experiences of 
other professional groups. While moral distress was initially 
delineated within nursing, the concept is relevant across other 
professional healthcare groups. Each occupation carries its own 
professional regulations, legal requirements, perception of clinical 
goals, and relational position with allied disciplines to be balanced 
against the individual practitioner’s moral framework.[3] Moral distress 
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has been reported by various diverse healthcare disciplines, including 
psychiatrists, podiatrists, psychologists, and physiotherapists.[4-9] 
Whilst it has historically received limited consideration in bioethical 
discourse, there is an emerging recognition that pharmacy is a value-
based profession with a strong ethical grounding.[10] In the past 
several decades, the pharmacy profession has sought to become 
more patient-focused, and to embrace an expanded role that shares 
responsibility for optimal drug-therapy outcomes. Pharmacists play 
an active and influential role in patient care, and are required to make 
clinical and ethical decisions regarding safe access to medicines and 
treatment. As pharmacists expand their roles, there are significantly 
more opportunities for ethical and moral problems to arise. 
Additionally, the commercial nature of community pharmacy can also 
present additional conflicts of interest that pharmacists must 
continue to address and resolve. These factors may be compounded 
by the fact that community pharmacists are generally more isolated 
from support networks than their hospital-based colleagues.   
Pharmacists working in the UK operate within a highly regulated 
occupational sphere and are bound by strict legal frameworks and 
codes of professional conduct. The extent of legal regulation of 
pharmacists compared to other healthcare professionals is marked: 
for example, a single error in the dispensing of medicines may be 
considered a criminal offence under s.64(1) of the Medicines Act 
1968. The law governing pharmacy practice dictates a complex array 
of professional duties and obligations that pharmacists must adhere 
to in the course of their work. Pharmacists that contravene the 
regulatory requirements risk removal from the Register of 
Pharmacists and loss of their right to practice. 
Pharmacy represents the third-largest regulated healthcare 
profession, with approximately 66,000 pharmacists currently 
registered to practice within the UK.[11]  Although pharmacists roles 
have developed in recent years to encompass fields including 
 Changes in UK pharmacy law in the early 21st century 
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primary care and public health,[12] the profession has traditionally 
operated within three areas: community; hospital; and the 
pharmaceutical industry. The community pharmacy sector 
incorporates over 11,700 pharmacies and employs approximately 71% 
of the pharmacy workforce.[13] Over one billion prescriptions are 
dispensed from community pharmacies each year.[13] Community 
pharmacists are often the first – and at times only – point of contact 
for members of the public seeking advice and support with regards 
to their health and wellbeing. Consequently, pharmacists practicing 
within this sector play a crucial role in the provision of clinical 
services, the delivery of public health initiatives, and the reduction of 
health inequalities.  
The regulated activities of pharmacy may be broadly categorised 
into three areas, namely: 
1. Licensing, sale, supply and administration of medicines;
2. Handling of controlled substances that have medical uses; and
3. Obtaining and retaining registration with the General
Pharmaceutical Council (GPhC).
These activities are governed by three discrete sets of regulations, 
each of which has undergone significant change in the past decade. 
The licensing, sale, etc. of medicines for human use is controlled by 
the Human Medicines Regulations 2012 (HMRs),[14] and – to a lesser 
extent – the Medicines Act 1968.[15] Control over access to controlled 
drugs (CDs) falls under the terms of the Misuse of Drugs Act 1971 and 
associated regulations, primarily the Misuse of Drugs Regulations 
2001.[16, 17] Finally, the regulation of the profession of pharmacy has, 
since 2010, been the remit of the GPhC, using powers imparted by 
the Pharmacy Order 2010,[18] and associated rules and guidance.[19-21] 
Neglecting to stay abreast of the manifold changes to pharmacy law 
or failing to understand how these changes affect the various 
restrictions placed on their practice, can leave pharmacists open to 
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criminal prosecution, civil actions, and fitness to practise proceedings 
overseen by the GPhC. 
As the legal frameworks and codes of professional conduct guiding 
pharmacists have been revised, so has the pharmacy profession 
sought to become more patient-focused and to embrace an 
expanded role that shares responsibility for optimal patient 
outcomes. Pharmacy is increasingly recognised as a value-based 
profession with a strong ethical grounding. A strict regulatory 
environment creates the potential for moral distress to occur due to 
the limitations it places on practitioners’ ability to act congruence 
with their own moral judgements. 
For example, pharmacists are permitted to supply diamorphine 
hydrochloride (heroin) to drug addicts provided that certain strict 
legal criteria are met (Chapter G). Making a supply other than under 
these criteria constitutes a criminal offence that can have potentially 
career-ending consequences. The treatment of addiction involves 
teams of healthcare professionals including case-workers, 
psychiatrists, and community pharmacists, often working in disparate 
locations. Errors can – and do – occur, putting the pharmacist in the 
position of making an unlawful supply in the best interest of the 
patient, or acting lawfully and placing the patient at risk of relapse. 
Even the most mundane aspects of medicines law can indirectly lead 
to situations in which pharmacists must balance the best interests of 
individual patients with those of the wider public. Parallel trade 
allows medicines to be procured from European markets at a fraction 
of the cost of those available from UK wholesalers (Papers A-C; 
Chapter F). No major ethical issues are raised by parallel imports in 
themselves as these products identical to those obtainable through 
the UK supply chain and provide significant cost savings to the 
NHS.[1, 2] However, patient autonomy may come into opposition with 
the commercial pressures inherent in servicing an NHS pharmacy 
contract (Fig. 1). Although the medicines themselves may be 
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identical, the packaging – which typically involves attaching English-
language labels onto the manufacturer’s packaging – identifies these 
products as foreign in origin. Where a patient incorrectly perceives 
these products as inferior and insists upon the UK variant of their 
medicine, the pharmacist may find themselves forced to yield to the 
patient at a cost to their own personal autonomy. 
Commentary 
Overview 
The publications in the following commentary are discussed under 
four headings, namely: the three legally regulated areas of pharmacy 
practice outlined above; and a fourth category dealing with moral 
considerations raised with respect to conscientious objection and 
moral distress. 
I have tried to be mindful of the University’s regulations, which 
outline specific requirements for the award of a PhD by 
Publication.[22] The publications submitted demonstrate “ability in 
conducting original investigations” using a range of methodologies 
employed over the course of the ten-year period during which this 
work was undertaken.[22](para. 5.1) The body of work includes a 
significant amount of both doctrinal and empirical legal research, 
each with their own set of methods and outcomes. 
Doctrinal legal research deals with verifying existing knowledge on 
legal issues, and typically involves studying existing laws, related 
cases and authoritative materials analytically. In contrast to literature 
review, content analysis or historical legal research, doctrinal 
research studies legal propositions based on secondary data of 
authorities such as statutory materials, court decisions, and guidance 
documents. 
The major purposes of doctrinal legal research include the following: 
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• to propose new laws, to test them, and add new knowledge to
legal scholarship;
• to help maintain continuity, consistency and certainty of law;
and
• to advise clients about the application of the law in specific
cases,[23]
each of which are in evidence in Papers A-D and H. 
The aim of empirical legal research, in contrast, is to investigate the 
role of regulations at play in society by empirical means. In the case 
of Paper E, quantitative methods are employed to determine how 
well pharmacists coped with legislative changes directly affecting 
pharmacy. 
Statistical methods employed in the course of this research included 
Poisson regression (Paper E),[24](pp. 740-752) and Pearson’s X2 test (Paper 
I).[25] Additionally, sampling adequacy was verified in Paper K using 
the Kaiser-Meyer-Olkin method, and Bartlett’s test and parallel 
analysis methods were used during the principle component 
analysis.[26, 27] 
In developing a tool to measure moral distress, a three-phase 
exploratory sequential mixed method design was employed.[28] An 
initial qualitative phase was followed by quantitative data collection 
and analysis (Paper K), with a final phase integrating the data from 
the two separate strands (Paper M). Initial data collection involved 
the convening of three semi-structured focus groups. Themes were 
derived by open coding, grouping and categorising of these data. 
Thirteen items were generated, which were subjected to content 
validity and reliability testing before undergoing principle component 
analysis and construct validity testing. 
Papers A-E, and H-L, represent a “significant and coherent 
contribution to the development of knowledge”, as defined by UEA 
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regulations,[22](para. 5.1) both as discrete works, and through their 
contribution to the development of an instrument to measure moral 
distress among community pharmacists (Papers J, L and M) (Fig. 1). 
 
Fig. 1: Flow chart (modified from Paper K) outlining how concepts 
examined in earlier papers were identified as triggers for moral 
distress, as determined in Papers J, K and M. 
Licensing, etc. of medicines 
Human Medicines Regulations 2012 
EU Council Directives on the licensing of medicines were first entered 
into UK law by the Medicines Act 1968,[15] which enabled 
approximately 200 Statutory Instruments (SIs) to be created over 
the course of the next 44 years. These regulations provided for the 
various types of licenses required by pharmaceutical manufacturers, 
as well as for the sale, supply, administration, import, and export of 
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medicines for use in humans and animals. In August 2012, during the 
period in which I was preparing Chapter F for publication, the HMRs 
came into force, with the twin aims of bringing the existing 
legislation into one set of regulations and simplifying the way these 
provisions were drafted. They set out a comprehensive regime for 
the authorisation of products; for the distribution of those products; 
for their labelling and advertising; and for pharmacovigilance. 
There are 17 parts of the HMRs as originally enacted, containing 349 
regulations, followed by 35 schedules. 
Parts 1 and 2 consolidate, with only minor and drafting amendments, 
the administrative provisions in Part 1 of the Medicines Act 1968  
Parts 3 to 9 govern the manufacture and importation of, and 
wholesale dealing in, medicinal products. After Part 4 establishes that 
products must not be sold, supplied, or offered for sale or supply in 
the United Kingdom unless authorised, Parts 5 to 8 provide for the 
procedures for authorisation by the United Kingdom licensing 
authority of medicinal products in various categories, namely: 
allopathic medicines (Part 5); homeopathic medicines (Part 6); 
traditional herbal medicines (Part 7); and unlicensed medicines 
required for public health reasons (Part 8). Additionally, these parts 
of the HMRs consolidate the corresponding parts of the 1968 Act 
with regulations affecting the licensing process.[29-31] 
Part 10 outlines various exemptions from the provisions outlined in 
Parts 4 to 8, many of which apply to pharmacists and persons 
conducting a retail pharmacy business. 
It is these parts (4-8, 10), accounting for more than one quarter of 
the 322 pages of the HMRs that are explained and evaluated in 
Chapter F. 




The body of work submitted in support of this application begins 
with three publications (Papers A-C), which together constitute a 
detailed examination of the legal underpinnings of trade in 
legitimately produced medicinal products sourced in parallel to the 
established supply chain. 
Unlike the licensing of medicines by the owner of the intellectual 
property rights, which have been regulated by statute since the 
enactment of the Medicines Act on 25th October 1968, the bringing to 
the market of parallel imports has its origins in common law. The 
historical context of this was the subject of Paper A. 
The interpretation by the Court of Justice (ECJ) of provisions within 
the Treaty of Rome which prohibit “quantitative restrictions on 
imports and all measures having equivalent effect … between 
Member States”,[32](Arts. 30-34) and how these must be balanced against 
prohibitions justified on “grounds of the protection of health and life 
of humans”,[32](Art. 36) were the starting point for the legalisation of the 
parallel trade in medicines.[33]  
Following this judgement, the European Commission produced a text 
outlining the basic principles for an abbreviated form of an MA for 
parallel-traded medicines.[34] Various stakeholders petitioned the ECJ 
with regard to specific definitions within this text, including 
“manufacture under license” and “the same group of companies”.[35, 
36] At the time of writing of this paper, an administrative document 
issued by the Department of Health was the only guidance available 
to those wishing to import medicines licensed elsewhere in the 
European Economic Area (EEA) into the UK. In the absence of any 
statutory provision for this legitimate activity, Paper C examined the 
pitfalls common to applications for a parallel import license and with 
supplying parallel imports to UK-based patients. Careful 
consideration was given to the additional legal challenges – this time 
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in reference to trademark infringement and market restrictions – that 
were brought by major pharmaceutical companies seeking to thwart 
parallel trade by other means.[37, 38] A critical analysis of these 
challenges was undertaken in Paper B. 
Provisions in relation to parallel import licences were omitted from 
Part 5 of the HMRs, and so the information in Papers A-C remained 
current after the reform of medicines law in 2012. It was initially 
unclear how the HMRs would apply to parallel import licences, if at 
all. Consequently, conditions and requirements essential for patient 
safety were omitted from the regulations and it was not clear, for 
example, if there was a power to vary suspend or revoke parallel 
import licences. In 2014, the Medicines and Healthcare products 
Regulatory Agency (MHRA) rectified this position so that the 
conditions and requirements in relation to such licences are now 
clearly set out in the Regulations.[39] As a result, Papers A-C now 
serve mainly as a historical record of the common law regulation of 
parallel imports.  
Controlled drugs 
Misuse of Drugs Regulations 2001 
Prior to 2004, the legislation relating to controlled drugs had barely 
changed in 20 years, since the introduction of the Misuse of Drugs 
Regulations 1985.[40] A large number of significant changes 
introduced from 2004 to 2007 were precipitated by the actions of 
Harold Shipman, who was convicted on 31 January 2000 of the 
murder of 15 of his patients while he was a General Practitioner in 
Hyde, near Manchester. He was sentenced to life imprisonment. In 
September 2000, the Secretary of State for Health, Alan Milburn MP, 
announced that an independent public inquiry would be held under 
the terms of the Tribunals of Inquiry (Evidence) Act 1921 to establish 
what changes to current systems of healthcare regulation should be 
made in order to safeguard patients in the future.  
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Dame Janet Smith, a High Court judge, was appointed Chairman of 
The Shipman Inquiry, the work of which began in February 2001. The 
inquiry's first report, published on 19 July 2002, found that, over a 
period of more than 20 years, Harold Shipman had secretly obtained 
very large quantities of diamorphine and subsequently used it to kill 
many of his patients.[41] Despite the regulatory controls in place, 
Shipman's diversion of diamorphine went undetected. When it did 
eventually come to light, it was not because his unlawful acquisition 
of the drug had been detected, but because he had come under 
suspicion of murdering Mrs Kathleen Grundy. The report made 
apparent that the regulatory framework governing the use of 
controlled drugs had not operated as it should. The purpose of 
regulation, according to the report, is to ensure accountability for the 
use of controlled drugs to avoid their diversion to improper use, and 
to detect such diversion if it occurs. 
Recommendations on the following issues were made: 
1. prescribing controlled drugs and prescriptions for controlled
drugs;
2. arrangements for security and record keeping for controlled
drugs in doctors' surgeries;
3. arrangements for security and record keeping for controlled
drugs in community pharmacies;
4. computerised record keeping;
5. inspection and monitoring of community pharmacies and
surgeries;
6. collection and delivery of controlled drugs in the community;
7. controlled drugs in the community and record keeping; and
8. administration, return, and destruction of controlled drugs in
the community.[42](Chapter 14; para. 14.1)
It is noteworthy that six of these eight issues lead to 
recommendations to tighten the controls on the handling of CDs 
within pharmacies, though Shipman himself was a general 
 Changes in UK pharmacy law in the early 21st century 
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practitioner (GP), not a pharmacist. At the same time, the UK 
Government was pursuing a policy of widening the roles of many 
non-medical health care professionals to include prescribing rights. 
The years 2004 to 2007, therefore, saw a series of legislative 
changes affecting community pharmacists in their routine work 
(Paper D). The effect of these changes on the practice of pharmacy 
was examined by retrospectively analysing enquiries to the National 
Pharmacy Association (NPA) (Paper E). 
Following the publication of Papers A-E , I was invited to contribute 
two chapters (F and G) to the 10th edition of Dale and Appelbe’s 
Pharmacy and Medicines Law, which was moving from a co-authored 
to an edited volume owing to the retirement of the authors. As 
outlined above, Chapter G examined a topic that had undergone 
significant change since the 9th edition was published four years 
previously. As I have already described, the law regulating the 
licensing of medicines (the subject of Chapter F) was repealed in 
2012. As such, both chapters had to be completely rewritten with 
reference to the new law in force. 
General Pharmaceutical Council 
Pharmacy Order 2010 
In addition to being subject to legal regulations regarding the 
handling of medicines and controlled drugs, pharmacists are also 
directed by guidance and standards published by the General 
Pharmaceutical Council.  
The GPhC is the body responsible the regulation of pharmacists, 
pharmacy technicians, and pharmacy premises in England, Scotland 
and Wales. It was created – along with the Royal Pharmaceutical 
Society (RPS) – from the Royal Pharmaceutical Society of Great 
Britain (RPSGB) in October 2010, in response to a government White 
Paper on the regulation of health professionals.[43] At that time, the 
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RPSGB acted as both the regulator for pharmacy, and also as the 
representative body responsible for leading the profession. The 
primary goal of the split was so that representative and regulatory 
functions of the pharmacy profession could be separated.[43](paras. 1.29-
1.36)
The main objective of the GPhC is to protect, promote and maintain 
the health, safety and well-being of members of the public who use 
or need the services of registrants. To that end, the Council is 
empowered by the Pharmacy Order 2010 to ensure that registrants 
adhere to such standards as it considers necessary for the safe and 
effective practice of pharmacy.[18](art. 5(1)) These standards initially took 
the form of a series of guidance documents, which were published in 
2010, covering areas including: education and training; pharmacy 
premises; and continuing professional development (CPD).[44-46] Also 
included in this collection of guidance documents was the GPhC’s 
Standards of conduct, ethics and performance.[47] 
These standards largely adopted the wording of the Code of Ethics 
for Pharmacists and Pharmacy Technicians developed by the 
RPSGB,[48] and were updated in 2012,[49] before being superseded by 
the current Standards for Pharmacy Professionals in May 2017.[50] The 
GPhC consider these standards a statement of what the public 
expect from pharmacy professionals, and reflective of what 
pharmacy professionals expect of themselves and their colleagues. 
Pharmacy professionals are expected to consider these standards, 
their legal duties, and any relevant guidance when making decisions 
related to their practice. Every registered pharmacist is personally 
accountable for meeting the standards and must be able to justify 
the decisions they make. 
Fitness to practise 
The Council has a statutory responsibility to ensure the continuing 
fitness to practise (FtP) of its registrants under art.4(3)(a) of the 
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Pharmacy Order 2010.[18] A registrant’s FtP may be impaired by 
reason of, for example, deficient professional performance, a criminal 
conviction, or failure to maintain standards set by the GPhC.[18](art.51(1))
Under the Fitness to Practise Rules, the GPhC may take action to 
restrict pharmacists’ ability to practise when this is necessary to 
protect patients and the public.[19] This is achieved through the 
conduit of the Fitness to Practise Committee (FtPC). 
If a pharmacist is referred to the FtPC, there will usually be a public 
hearing.[51, 52] The hearing is an adversarial process during which 
witnesses, including the registrant, may be examined and cross-
examined. If the committee concludes that the pharmacist’s fitness 
to practise is impaired, it may impose a sanction, up to and including 
removal of the pharmacist’s name from the Register of Pharmacists. 
Once the committee has made a decision, it makes a formal 
statement announcing its decision and explaining the reasons for it.
These decisions are published online by the GPhC. 
Additionally, if, at any point during an investigation, the Registrar of 
the GPhC is satisfied that it is necessary for the protection of 
members of the public, or is otherwise in the public interest, he may 
direct the FtPC to suspend a pharmacist’s registration by issuing an 
interim order.[18](art. 56)(1)) The committee has the authority to impose an 
order for up to 18 months, subject to a review every 6 months that 
the order is in force. 
Consequences to pharmacists for failing to meet legal requirements 
or to adhere GPhC standards can be severe. It is, therefore, of 
interest to know how the GPhC interpret these standards when 
assessing a registrant’s fitness to practise. Papers I and L are both 
concerned with the functioning of the GPhC’s Fitness to Practise 
Committee. The former examines whether circumstances described 
as warranting erasure from the Register of Pharmacists by GPhC 
guidance do actually lead to that outcome, and whether aggravating 
and mitigating factors considered by the committee when imposing 
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sanctions are first considered when determining impairment of 
fitness to practise. The latter paper critically compares the processes 
carried out with those of three different jurisdictions based on 




One piece of GPhC guidance that proved to be particularly 
contentious was the Guidance on the provision of pharmacy services 
affected by religious and moral beliefs, published in 2010.[53] Although 
the legal status of emergency hormonal contraception (EHC) is not in 
question, the law serves only to remove prohibitions on supply; it 
does not compel any pharmacist to supply the “morning-after pill” 
against their own religious or moral beliefs. Statute could force 
pharmacists to provide every service legally requested, if access to 
treatment was more highly regarded than religious freedom. While 
usually taking a deontological approach to the formulation of its 
guidance, the GPhC adopted a pragmatic posture in the face of the 
potential opposition of clinical and religious viewpoints on EHC. In 
Paper H, the argument is made that the GPhC should either assert 
that those with strong and sincere objections to performing a basic 
and routine aspect of their profession should not take up that 
profession, or that pharmacists not wishing to supply EHC should not 
be forced to do so, as it compromises their professional autonomy 
and does not fit with the principle of non-maleficence. Instead they 
adopted the pragmatic position that “women should be referred to 
an alternative appropriate source of supply available within the time 
limits for EHC to be effective”.[53] However, the guidance fell short of 
instructing pharmacists that they must supply the EHC themselves 
should they be unable to relay the patient to an alternate supplier 
within that timescale. A major success of this paper was that it 
started a chain of events leading to the publication of a new 
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guidance document, In practice: Guidance on religion, personal 
values and beliefs, in June 2017 (see Impact, below).[54] This included 
a hardening of the stance on a pharmacists’ right to refuse treatment 
to clinically appropriate patients by insisting that “they should take 
steps to make sure the person asking for care is at the centre of their 
decision-making, so they can access the service they need in a timely 
manner and without hindrance” and introducing a requirement to 
“[think] in advance about the areas of their practice which may be 
affected and making the necessary arrangements, so they do not find 
themselves in the position where a person’s care could be 
compromised.”  
Moral distress 
The requirement for pharmacists to act in a manner that is 
incongruent with their religious or moral beliefs highlighted in Paper 
H prompted a line of research leading to three further publications 
(Papers J, K and M) investigating the phenomenon of moral distress 
among community pharmacists in the UK. As described above, moral 
distress arises from situations in which the individual identifies the 
morally right action but feels unable to act accordingly due to some 
other legal or organisational constraint. 
Paper J identifies that the work of community pharmacists is subject 
to strict legal frameworks and codes of professional conduct. This 
regulatory environment, when taken together with the recognition of 
pharmacy as a profession with a strong ethical grounding, creates 
the potential for moral distress to occur as practitioners are 
prevented from acting in congruence with their own ethical 
judgements. Studies assessing incidence of moral distress in other 
healthcare professions are reviewed,[4-9, 55-59] together with a single 
study assessing the phenomenon in pharmacists working within 
Sweden’s healthcare system.[60, 61] 
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The lack of a validated tool to quantify moral distress in UK-based 
community pharmacists is identified. A strategy is developed to 
address the following: the situations causing moral distress for 
community pharmacists; the extent to which these pharmacists 
experience moral distress in their working lives; and what, if anything, 
can predict the level of moral distress experienced.  
The lack of an appropriate tool is remedied in Paper K, which 
describes the three-phase exploratory, sequential mixed-method 
development of such an instrument.[28, 62] Qualitative methodology 
was used to explore moral distress from the perspective of practicing 
community pharmacists and to identify the pharmacy practice 
situations that they associate with experiences of moral distress. The 
qualitative findings were used to inform the development of an 
instrument to capture data regarding the intensity of moral distress 
and the frequency of its occurrence as experienced by community 
pharmacists. The survey involved rating individual practice-based 
scenarios for both frequency and intensity of moral distress using a 
seven-point Likert Scale. It was subjected to content validity testing 
before being trialed with a pilot sample. The results of the pilot 
sample were subsequently used to carry out construct validity and 
reliability testing. The final questionnaire differed markedly from 
those described in Paper J, which use cumulative scoring, despite the 
absence of a known and quantifiable relationship between intervals 
upon which this is premised. 
The instrument was distributed as a self-administered online survey, 
which gave rise to a dataset containing responses from almost 600 
full-time community pharmacists (Paper M). Major triggers for moral 
distress in UK-based community pharmacists were identified, and 
possible underlying causes of moral distress were examined in the 
light of these. 
During the focus group sessions described in Paper K, many of the 
rules and regulations affecting practice identified in the preceding 
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papers and chapters were identified as sources of moral distress. 
Scenarios describing several of these were subsequently included in 
the questionnaire described in Paper M, including: dispensing of 
controlled drugs (Papers D and E; Chapter G); supply of 
unauthorised medicines in an emergency; prescribing medicines 
outside their licensed indications (Chapter F); supply of EHC (Paper 
H); and the economical provision of drugs (Papers A-C) (Fig. 1). 
The knowledge that contravention of the these regulations may 
constitute a criminal offence, and may additionally establish an 
impairment of fitness to practise under the GPhC’s Fitness to Practise 
Rules,[19] as highlighted in Paper K and described in Paper I, can 
create a barrier to acting morally, which is an essential component 
for moral distress. Fear of being struck off the Register of 
Pharmacists following a protracted fitness to practise investigation, 
as described in Papers I and L, was cited as the major driver to 
acting against their own moral judgement 
The results of Paper M describe for the first time the frequency and 
severity with which moral distress is experienced by community 
pharmacists in the UK. Nearly three-quarters of the respondents 
rated the intensity of distress associated with the inability to 
dispense CDs as moderate or above. Previous research involving UK 
pharmacists has highlighted accounts of dilemmas involving this 
practice scenario.[63, 64] This reflects the data gathered during the 
qualitative phase of the work (Paper K), which indicated that the 
distress allied to this practice situation was of a particularly high 
intensity. During focus groups, participants described situations in 
which they felt confident that the request made by the patient was 
legitimate, but that the required procedural aspects of dispensing 
could not be complied with due to absent or incorrectly written 
prescriptions, which were additionally presented at a time when 
sourcing a replacement was logistically difficult. 
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Some triggers identified as significant in focus groups held during 
the development of the questionnaire (Paper J) were not 
subsequently associated with high moral distress scores in the 
national sample. During focus groups, pharmacists described a 
growing sense of powerlessness to ultimately influence the patient’s 
decision on the relative effectiveness of treatments, including parallel 
imports (Papers A-C) and non-proprietary medicines (Chapter F). 
During the group discussions, acquiescing to the patient’s requests 
despite believing this to be contrary to their best interests was 
primarily framed as a means of de-escalating conflict. Ultimately, 
supplying medicines at the insistence of the customer in instances 
where this conflicted with their own professional judgement was 
associated with moral distress of moderate intensity experienced 
relatively infrequently for many pharmacists. Although the use of 
parallel imports first discussed in Paper A did seed discussions in the 
development of the moral distress questionnaire, it did was not 
ultimately cause of severe distress in the overall population. 
Some low-scoring items on the questionnaire were examined to 
determine how their negative effects were minimised, with a view to 
applying similar approaches to the minimisation of distress in high-
scoring scenarios. EHC was found to generate low levels of moral 
distress in terms of both frequency and intensity. EHC has been 
highlighted as an area of ethical concern for UK pharmacists:[65, 66] 
however, the results in Paper M indicate that most pharmacists do 
not experience moral distress in this regard. It was argued in Paper H 
that the GPhC’s approach to conscientious objection is 
philosophically unsatisfactory: however, it does appear to have a 
positive in terms of its effect on the frequency at which this scenario 
generates moral distress in practice. 
Potential mechanisms for reducing the incidence of moral distress for 
this professional group are considered in Paper M, in which the 
conclusion was reached that the reduction in the frequency of 
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occurrence of moral distress is best achieved by the creation of 
morally habitable workplaces, where possible triggers can be 
identified and avoided. A meaningful intensity reduction, associated 
with increased moral competency or moral agency, can be achieved 
through structured undergraduate ethics education and accessible 
postgraduate training and resources. 
Journal selection 
My research in pharmacy ethics and law has always been targeted at 
practising pharmacists, lawyers engaged in professional regulatory 
practice and policymakers, in addition to members of the academic 
community. In order to ensure that the latter group are not the only 
beneficiaries of this work, I initially targeted publications that could 
be accessed by all interested parties, not just those with access to 
academic library catalogues. 
The Pharmaceutical Journal (PJ) was the official journal of the RPSGB 
from its foundation in 1841 until its dissolution in 2010.[67] From July 
1870 until September 2010, it was delivered to all UK-registered 
pharmacists on a weekly basis. As such, it was often the publication 
of choice for academic researchers wishing to inform practising 
pharmacists of outcomes with relevance to the day-to-day practice 
of their profession. High-quality, peer-reviewed research of particular 
interest to practitioners, including, for example: examining changes in 
patterns of misuse of over-the-counter medicines;[68] exploring 
prescribing errors in general practice;[69] or investigating the 
incidence and nature of drug-related hospital admissions,[70] was 
often published in the PJ, to reach the largest audience for whom it 
could provide benefit. Prior to 2010, I regularly published articles 
intended to inform or influence practising pharmacists – as well as 
those targeted at pharmacy policymakers – in the PJ.[71-73] 
From 2011, I have mostly published research in the area of pharmacy 
ethics and law in the International Journal of Pharmacy Practice (2018 
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impact factor: 1.310), the International Journal of Clinical Pharmacy 
(2018 impact factor: 1.692), and Research in Social and Administrative 
Pharmacy (2018 impact factor: 2.719). Although not as broadly 
distributed as the PJ once was, articles published in these journals 
have been widely reported through national and international news 
outlets,[11, 74-79] including the PJ,[80, 81] ensuring that they are brought to 
the attention of those practising pharmacy outside academia. 
Paper H was published in the Journal of Medical Ethics (2018 impact 
factor: 2.195; ranked #3 for bioethics).[82]  
Contribution to the development of understanding 
Impact 
Peer-review has been a formal part of scientific communication since 
the first scientific journals appeared more than 300 years 
ago.  Despite many criticisms about the integrity of peer-review, the 
majority of the research community still believes it is the best 
method for assessing the contribution to the development of 
understanding made by a program of research.[83] As with any 
submission for a PhD by Publication, this assessment has – by 
necessity – been made in advance of the thesis being submitted for 
examination. However, publication is no longer the only manner by 
which the substance and significance of the research is assessed.  
The Research Excellence Framework (REF) is the UK’s system for 
assessing the quality of research in UK higher education 
institutions. In 2014, for the first time, it took the impact of research 
into account in its evaluation of quality.[84](para. 10a) Impact, in this 
context, is defined as “an effect on, change or benefit to the 
economy, society, culture, public policy or services, health, the 
environment or quality of life, beyond academia.” In addition to their 
acceptance in peer-reviewed journals, several of the papers 
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submitted here have a wider impact in the regulation of pharmacy in 
the UK. 
Conscientious objection 
Since its formation, the GPhC has supported the right of individual 
pharmacists to “conscientiously object” to the provision of EHC to 
clinically suitable patients on religious or ethical grounds. Following 
the meeting of the governing council of GPhC on 12 April 2012, Chief 
Executive and Registrar Duncan Rudkin said that the council would 
not be changing Standard 3.4 of the Standards of Conduct, Ethics 
and Performance, which allows pharmacists to refuse to supply EHC 
provided certain criteria are met. Mr Rudkin stated, “We're not aware 
of any particular conflict and the council doesn't see any case for 
changing [the standards] at the moment”.[85] 
Paper H, published in the Journal of Medical Ethics on 31 January 
2013 called for the GPhC to either enhance, or do away with, 
“conscience clauses” in respect to the supply of EHC. It received 
extensive press coverage on both print and on-line media, including 
The Scotsman, The Yorkshire Post, The Northern Echo and The Daily 
Telegraph (Fig. 2).[11, 74-76, 78, 79, 86] 
The GPhC’s initial response to the article was, again, to emphasise 
that the current standards on the provision of pharmacy services 
affected by religious and moral beliefs were adequate.[80] In an 
interview published in The Pharmaceutical Journal, Mr Rudkin stated 
that the existing standards “remind pharmacists that they must not 
discriminate against patients on the grounds of religion, belief, 
lifestyle or for any other reason.”  
 




Fig. 2: Collage of press clippings from 31 January 2013 citing 
research published in the Journal of Medical Ethics (Paper H).          
(© Newspaper Licensing Agency.) 
As interest increased and further articles were published,[81, 87, 88] the 
GPhC released a further statement to the press.[89] On 8 February 
2013, the GPhC “pledged to review pharmacists’ right to refuse to 
supply emergency contraception”. Mr Rudkin stated that “the GPhC 
will launch a patient consultation, set to begin at the start of 2014, in 
an attempt to gauge opinion on whether pharmacists should be 
allowed to refer patients to other providers if they have a moral or 
religious objection to dispensing emergency contraception 
themselves”. It was a “huge piece of work” and there were strong 
views on both sides, Mr Rudkin warned. On 24 June 2013, The GPhC 
announced that “conscience clause will face an official review after 
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fresh criticism … of powers that allow pharmacists to refuse services 
on religious grounds”.[90] 
In its corporate plan for 2014-15, the GPhC published a timescale in 
which this work will be carried out as part of the review of its 
standards of conduct, ethics and performance.[91] The resulting public 
consultation closed on 7 March 2017.[92] The guidance document, In 
practice: Guidance on religion, personal values and beliefs, published 
on 22 June 2017, included provision that pharmacists must 
“recognise their own values and beliefs but [must] not impose them 
on other people.”[54] The conscience clause, whereby a pharmacist 
choosing not to supply Emergency Hormonal Contraception could 
refer women to an alternative appropriate source of supply available 
within the time limits for EHC to be effective,[93] was replaced with a 
requirement to make the necessary arrangements in advance, so 
they do not find themselves in the position where a person’s care 
could be compromised.[54] 
Fitness to practise 
On 3 November 2014, Paper I, examining the fitness to practise 
procedures of the GPhC, was published in the International Journal of 
Pharmacy Practice.[51] Again, I was contacted by the press to provide 
some quotation to give context to their coverage. When asked if the 
GPhC would be acting on the findings, Mr Rudkin stated that “the 
GPhC [would] reflect on the researchers’ findings”.[94] On 20 
November, the GPhC published a discussion document outlining 
proposed changes to the guidance that the Fitness to Practise 
Committee use in reaching decisions. This was followed on 17 
February 2015 by the launch of a public consultation, closing on 31 
March, which proposed changes to the guidance that fitness to 
practise committees use in reaching decisions.[95] The document, 
Good decision making: fitness to practise hearings and sanctions 
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guidance, came into effect on 20 July 2015,[96] replacing the previous 
indicative sanctions guidance.[97] 
Limitations 
Given that this body of work spans over ten years of practice in a 
rapidly changing occupational sphere, it is to be expected that some 
of the earlier research is now of historical, rather than contemporary, 
interest. Although extremely relevant at the time of their publication 
in 2008, Papers A-C examine a set of common law processes that 
largely ceased to apply following the amendment of the HMRs in 
2014. Whilst the HMRs and Pharmacy Order should continue to apply 
(subject to minor amendments) for many years to come, it is likely 
that the Misuse of Drugs Regulations will be significantly updated in 
the short-to-medium term. 
It must be noted at this point that not all possible triggers identified 
from the earlier paper were reported to ultimately give rise to moral 
distress to the same extent, if at all. Although several issues reported 
in the literature, such as CDs dispensing and time constraints did 
generate significant distress, others including EHC did not. 
The use of a frequency scale within the moral distress questionnaire 
was not meaningful for those pharmacists working on a part-time 
basis and a large volume of participants were subsequently parsed 
from the sample. This element of the design ideally requires 
modification before any further use. However, the results indicate 
that the current instrument is both valid and reliable. 
Future work 
In Paper M, it is acknowledged that a reduction in moral distress 
scores may not be indicative of growing moral competence or 
morally congruent practice but may instead reflect a reduction in 
moral sensitivity and ethical engagement. Further research is 
required to further explore the relationships between moral distress 
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and other aspects of ethical decision-making, particularly moral 
sensitivity and moral reasoning. A greater understanding of the 
relationship between moral distress and moral decision-making 
would inform potential educational interventions to reduce moral 
distress. 
There is significant scope to create and evaluate educational 
initiatives to reduce moral distress within this occupational sphere. It 
is vital that interventions are developed to support individuals while 
targeting the external mediators of moral distress, including the 
moral habitability of the community pharmacy environment. Further 
research is required to develop and evaluate interventions that aim 
to enable practitioners to reflect on their experiences of moral 
distress and take positive action in response to them. Exploring 
reflective practice may be pivotal in the development of 
interventions aiming to reduce the incidence of moral distress by 
fostering the development of moral competency and the enactment 
of moral agency.  
Summary 
The degree of PhD by publication is required to meet the same 
standards for award of a traditional PhD.[22](para. 7.4) The requirement 
for a PhD to make a “significant contribution to understanding” is 
traditionally assessed through peer-review. The body of work 
submitted in pursuit of this award includes no fewer than eleven 
peer-reviewed publications. The analysis of each of the three areas of 
pharmacy law that have undergone major change in the early 21st 
century have given rise to at least two discrete publications each, 
while also contributing to research examining the phenomenon of 
moral distress in pharmacists, which itself led to a further three 
publications. A range of techniques including doctrinal and empirical 
legal research; and a range of quantitative and qualitative 
methodologies were employed at each stage of this coherent body 
of work. 
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In addition, this work has had significant impact outside academic 
circles. Within the context of interdisciplinary legal research, the 
desired outcome is to facilitate a future change, either in the law 
itself, in the manner of its administration, or in its effects on those 
who work within the area it seeks to regulate. Elements of this 
research have influenced the direction of the regulation of the 
pharmacy profession with respect to both withholding treatments on 
moral or religious grounds and fitness to practise. 
Collaboration 
The body of work supporting this submission was carried out 
between May 2008 and January 2019 in my capacity as a member of 
academic staff with the School of Pharmacy at the University of 
Hertfordshire. With the exception of Chapters F and G, all of the 
publications were co-authored. In each case, I was the principal 
investigator and corresponding author. Written confirmation by at 
least one co-author per published work is provided in Appendix II, in 
accordance with university regulations.[22](para. 5.2(2)) 
Jayne Astbury (Papers J, K and M), Victoria Greenland (Paper I), 
Adrienne Hickman (Papers D, E and I), Lisa McDonald (Paper H), 
Fatima Mukhtar (Paper K), and Toorpakiy Sarfaraz (Paper L) were all 
students working under my supervision. 
Alice Holton (Paper H) was a student working under the supervision 
of Prof. Paul Gallagher (Paper H) at the Royal College of Surgeons in 
Ireland (RCSI). Paul provided a historical context for the use of EHC 
in the Republic of Ireland, and to detail its current legal status in that 
jurisdiction. 
Richard O’Neill (Papers A, B, C and J) was Associate Head (and, 
latterly, Head) of the School of Pharmacy from 2005 until his 
retirement in 2015. At the start of my academic career, he was 
assigned as my mentor as part of the university’s probationary 
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process for new staff. Richard’s revised these papers, excising 
redundant text and providing advice on the structure of what 
remained. Additionally, Richard ensured that I was provided with 
protected time to dedicate to research and writing and allowed me 
to trade in the value of his name within the academic pharmacy 
community when applying for grant funding in support of my work. 
As Head of Pharmacy Services at the NPA, Leyla Hannbeck (Paper E) 
provided access to call logs from their Information Services 
department for analysis. 
Robert Flynn (Paper E) was a lecturer in pharmacy practice at the 
University of Hertfordshire from October 2010 to September 2011. 
Together, we processed the data that would form the basis of Paper 
E.  
Betty Chaar (Paper K) is an associate professor in pharmacy law and 
practice at the University of Sydney. Betty provided confirmation 
that the narrative relating to the each state or territory’s enactment 
of Australia’s “National Law” was accurate,[98] and provided insight as 
to the nature and extent of guidance received by pharmacy tribunal 
members.
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